Clinically, a phase 1 study of HDAC inhibitor romidepsin and hypomethylating agent 5-azacytidine exhibited marked activity in patients with PTCL, with ORR and CR of 73% and 55%, respectively [32]. The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.